Get the Stockscreener App
253.86
0.47%
1.20
Ascendis Pharma A S stock is traded at $253.86, with a volume of 390.36K.
It is up +0.47% in the last 24 hours and up +6.66% over the past month.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
See More
Previous Close:
$252.66
Open:
$254.4
24h Volume:
390.36K
Relative Volume:
0.53
Market Cap:
$16.65B
Revenue:
$1.01B
Net Income/Loss:
$581.90M
P/E Ratio:
28.61
EPS:
8.8733
Net Cash Flow:
$50.57M
1W Performance:
-2.74%
1M Performance:
+6.66%
6M Performance:
+7.85%
1Y Performance:
+50.83%
1-Day Range:
$251.99
$258.86
1-Week Range:
$249.99
$263.26
52-Week Range:
$160.86
$282.15
Ascendis Pharma A S Stock (ASND) Company Profile
Compare ASND vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S
|
253.86 | 16.65B | 1.01B | 581.90M | 50.57M | 8.8733 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-25 | Initiated | Raymond James | Strong Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| May-05-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-16-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | UBS | Buy |
| Sep-05-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-25-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Initiated | Stifel | Buy |
| Dec-20-23 | Initiated | Jefferies | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Neutral |
| Apr-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-04-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-03-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Aug-30-22 | Resumed | Berenberg | Buy |
| Mar-28-22 | Resumed | Wedbush | Outperform |
| Mar-15-22 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-14-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-06-22 | Initiated | Cowen | Market Perform |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-20-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-30-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-11-21 | Resumed | Stifel | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Mar-20-20 | Initiated | Oppenheimer | Outperform |
| Oct-11-19 | Initiated | Morgan Stanley | Overweight |
| Mar-25-19 | Initiated | Evercore ISI | Outperform |
| Jan-24-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-19 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-18 | Initiated | Stifel | Buy |
| Apr-02-18 | Reiterated | Leerink Partners | Mkt Perform |
| May-11-17 | Initiated | JP Morgan | Overweight |
| Mar-09-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Feb-09-17 | Initiated | Credit Suisse | Outperform |
| Sep-26-16 | Initiated | Wedbush | Outperform |
View All
Ascendis Pharma A S Stock (ASND) Latest News
Artisan Small Cap Fund Trimmed Ascendis Pharma (ASND) Amid Lawsuit Concerns - Yahoo Finance
Ascendis Pharma AS (STU:A710) Shiller PE Ratio : (As of Jul. 24, 2026) - GuruFocus
Goldman Sachs Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $300 - 富途牛牛
Ascendis Pharma (ASND) Could Be 14% Below Fair Value As Growth Hopes Hold - simplywall.st
Ascendis Pharma (ASND) Shows High Growth Momentum With Bull Flag Breakout Setup - ChartMill
Ascendis Pharma A/S (ASND) Stock Analysis: Unpacking a 15.68% Potential Upside for Investors - DirectorsTalk Interviews
Tranche Update on Ascendis Pharma A/S's Equity Buyback Plan announced on February 12, 2025. - marketscreener.com
Ascendis Pharma A/S (ASND) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
(ASND) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
ASND5566766 Bond Profile — Key Metrics - TradingView
Price to earnings forward of Ascendis Pharma A/S – DUS:A710 - TradingView
Ascendis Pharma (ASND) grants 14,060 employee warrants at $265.57 - Stock Titan
Enterprise value to EBITDA forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
BofA raises Ascendis Pharma stock price target on revenue outlook By Investing.com - Investing.com India
Enterprise value to EBITDA forward of Ascendis Pharma A/S – DUS:A710 - TradingView
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $306 - Moomoo
BofA raises Ascendis Pharma stock price target on revenue outlook - Investing.com
Ascendis Pharma: Precision in Princeton - New Jersey Business Magazine
Ascendis Pharma A/S (ASND) Stock Analysis: A Biotech Giant with 144% Revenue Growth and Strong Buy Ratings - DirectorsTalk Interviews
Price to sales forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Enterprise value to EBIT forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Ascendis Pharma (ASND) Reports Two Year YUVIWEL Trial Data In Achondroplasia - Yahoo Finance
Enterprise value to revenue forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Ascendis Pharma (ASND) Says 104 Week TransCon CNP Data Still Looks Strong - simplywall.st
Ascendis Pharma (ASND) Stock Looks Above Fair Value As Shares Jump 24% - Yahoo Finance
Price to earnings forward of Ascendis Pharma A/S – BIVA:ASND1/N - TradingView
Enterprise value to revenue forward of Ascendis Pharma A/S – BIVA:ASND1/N - TradingView
Enterprise value to EBITDA forward of Ascendis Pharma A/S – BIVA:ASND1/N - TradingView
Ascendis Pharma : ASND - 24/7 Wall St.
Ascendis Pharma Stock's Strong Momentum to Continue, Wedbush Says - Moomoo
Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $327 - Moomoo
Ascendis Pharma (ASND) Investor Update Summary - Quartr
Ascendis Pharma (ASND) Q3 2025 earnings summary - Quartr
Ascendis Pharma (ASND) Q3 2024 earnings summary - Quartr
Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $345 - Moomoo
Ascendis Pharma (ASND) Study Update Summary - Quartr
RBC Capital Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $280 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
RBC Capital Adjusts Ascendis Pharma Price Target to $280 From $275, Maintains Outperform Rating - marketscreener.com
Ascendis Pharma A/S (ASND) Stock Analysis: Strong Buy Ratings and Promising Revenue Growth Capture Investor Interest - DirectorsTalk Interviews
ASNDAscendis Pharma A/S Volatility & Greeks - Finviz
Ascendis Pharma (ASND) Could Be 7% Undervalued Following Fresh ApproaCH Trial Data - simplywall.st
Ascendis Pharma Q2 2025 Earnings Preview - MSN
Ascendis Pharma: Behind The Stock Surge - Seeking Alpha
Ascendis Pharma added to Russell 3000, Russell 1000 and other US indexes - MSN
Ascendis Pharma Unveils Two-Year Pivotal Trial Data for TransCon CNP in Children With Achondroplasia - TipRanks
Ascendis Pharma (ASND) shares 2-year TransCon CNP ApproaCH achondroplasia results - Stock Titan
Ascendis Pharma A/S Announces New Radiographic Data from Week 104 of the Completed Pivotal Approach Trial of Once-Weekly Transcon Cnp in Children with Achondroplasia - marketscreener.com
Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial - TipRanks
Ascendis Pharma A/SAnnounces Week 104 Data From Approach Trial Of Transcon CNP In Children With Achondroplasia - TradingView
Ascendis drug data show leg alignment kept improving through 2 years - Stock Titan
Ascendis Pharma A S Stock (ASND) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ascendis Pharma A S Stock (ASND) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
May 29 '26 |
Buy |
223.12 |
500 |
111,562 |
900 |
| SMITH SCOTT THOMAS | EVP & Chief Financial Officer |
May 29 '26 |
Buy |
223.32 |
250 |
55,830 |
4,267 |
| BIENAIME JEAN JACQUES | Director |
May 26 '26 |
Buy |
237.80 |
400 |
95,120 |
400 |
| JENSEN FLEMMING STEEN | See Remarks |
May 11 '26 |
Sale |
238.49 |
19,460 |
4,641,021 |
0 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):